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INTRODUCTION
A frequency of 1% to 3% in patients exposed to
unfractionated heparin (UFH) for more than four
days may develop a heparin-platelet factor 4 anti-
bodies mediated thrombocytopenia (1), known as
heparin-induced thrombocytopenia (HIT) (2). Usual
HIT exhibits platelet count typically20103 /μL,
and spontaneous bleeding is unusual in contrast to
idiopathic thrombocytopenic purpura with platelet
count10103 /μL and clinical bleeding (3). The
major clinical problem associated with HIT is throm-
bosis, known as the heparin paradox. Delayed-
onset HIT was quite rare and seemed to account
for about 3 to 5% of all HIT cases (4). HIT with
thrombotic complications after cardiac surgery un-
der cardiopulmonary bypass (CPB) seemed to be
associated with high mortality (5). In this report,
an extremely rare case with delayed-onset severe
HIT with bleeding symptoms, without thrombosis,
after total arch replacement is described with ulti-
mate recovery.
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Abstract : An extremely rare case with delayed-onset heparin-induced thrombocytopenia
(HIT) is described. A 46-year-old man underwent arch replacement for aortic dissection
under cardiopulmonary bypass and initial exposure of unfractionated heparin. In post
operative 7 days, persistent atrial fibrillation was occurred, so a continuous infusion of
heparin (10000 IU/day) and Vitamine K antagonist (Warfarin) taking was started for
preventing thrombosis. By 32 days after the operation, his platelet count had fallen (3
103 /μL) and oral hematoma and ecchymoma of bilateral lower legs were occurred. The
value of HIT antibodies and the IgG antibody was 2.485 and 1.586 on 32-postoperative
day, respectively. Heparin was immediately discontinued, and argatroban administrated.
Platelet exceeded above 100 103/μL on 12 days of the therapy. To our knowledge, few
cases of delayed-onset severe HIT associated with CPB surgery have been reported in
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CASE
46-year-old man with chest pain was referred to
our hospital for acute type A aortic dissection. He
underwent emergent total arch replacement under
CPB. 110103 IU of UFH was given intravenously
during CPB, which was initial exposure of heparin
to him. When symptomatic atrial fibrillation (Af) was
developed on postoperative day (POD) 7, a con-
tinuous intravenous administration of UFH (10103
IU/day) was added and warfarin was started. Sinus
rhythm resumed by cardioversion on POD 9. For
preventing cardiogenic thromboembolism due to
recurrent Af, UFH administration had been contin-
ued for the warfarin control achievement of PT-
INR of 1.5-2.5. Finally, total UFH administration
was kept for POD16.
Platelet count decreased to 56103 /μL on POD
3 after cardiac surgery under CPB and increased
gradually as usual to 420103 /μL on POD 17.
But it promptly decreased again to 3103 /μL on
POD 32, 16 days after re-exposure of UFH (Fig. 1).
Spontaneous oral submucosal hematoma and ecchy-
moma of bilateral lower legs requiring special atten-
tion were found at the same time. But thrombo-
sis such as deep vein thrombosis and pulmonary
embolism, venous limb gangrene, cerebral sinus
thrombosis, stroke and acute myocardial infarction,
was not found clinically and by contrast CT and
echography.
As he had not taken medicines that caused throm-
bocytopenia and was not combined with severe in-
fection and/or disseminated intravascular coagula-
tion (DIC) associated diseaase, the presence of HIT
syndrome was suspected. Warfarin was immediately
discontinued, and argatroban, direct thrombin in-
hibitor, was immediately administrated at a dose of
0.5-2.5 μg/kg/min because of slight hepatic im-
pairment. Target APTT of its treatment was 1.5-2.0
times normal APTT score. Serologic tests confirm-
ing antibodies against heparin-platelet factor 4 com-
plexes, commonly known as HIT antibody, were
performed. The optical density (OD) values of HIT
antibody were 2.485, 2.314 and 2.116 on POD 32,
33 and 34, respectively (Table 1). The results
greater than 2.00 OD value were assessed as a very
strongly positive immunoassay result, which showed
the probability of detecting platelet-activating anti-
bodies was approximately 90%. In particular, clini-
cally important heparin- platelet factor 4-IgG anti-
bodies detected by peculiar enzyme immunoassay
were 1.586, 1.640 and 1.479 OD values on POD 32,
Fig 1. The course of platelet count, the level of heparin- induced thrombocytopenia (HIT) antibody and anticoagulant therapies
after total arch replacement. (Plt ; platelet, Af ; Atrial fibrillation)
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33 and 34, respectively. The values of HIT antibod-
ies and the IgG antibody of the preoperative stock
blood serum were negative. Futhermore, the value
of D-dimer, fibrinogen degradation products (FDP)
and thrombin-antithrombin complex (TAT) in-
creased on POD 32, respectively. It was resembled
the results of DIC. These results did not contradict
the HIT theory.
Platelet count exceeded above 100103 /μL on
12 days of the therapy, and warfarin was reintro-
duced for a PT-INR of 1.5-2.5 and argatroban was
discontinued. Hemorrhagic events had not been ex-
acerbated, and no thrombosis had been appeared.
Warfarin was reduced and discontinued with HIT
antibody under the cut off level on POD 126.
DISCUSSION
Critical assessment of HIT suggests a frequency
of 0.2 to 5.0 percentage in patients exposed to hepa-
rin for more than four days. Particularly, the inci-
dence of HIT in patients who underwent cardiac
surgery under CPB has been estimated to be 1.9%
(6). Without prompt diagnosis and proper treat-
ment, patients with HIT complicated with venous
and/or arterial thrombosis often result in dismal
outcomes, with limb amputation in approximately
10%, and death in about 20%-30% (7).
Typical-onset HIT usually occurs at 5-14 days
after initial exposure to a prophylactic or therapeu-
tic dose of heparin (4). Furthermore, the peak on-
set is 5 to 8 days after starting heparin therapy (8).
Meanwhile, delayed-onset HIT begins with objec-
tively proven venous and/or arterial thrombosis,
with prompt thrombocytopenia developing after
re-exposure of heparin following withdrawn of pre-
vious heparin. It seems to develop after re-expo-
sure at a median time of 14 days (range : 9 to 40
days) (9). In this case, the thrombocytopenia of the
nadir platelet count of 3103 /μL occurred promptly
at 32 days from the initial exposure to heparin for
CPB, and 16 days from the re-exposure to heparin
for Af.
HIT is usually caused by IgG antibodies that are
reactive against complexes of platelet factor 4 and
heparin. The key factor of delayed-onset HIT seems
to be antibodies that activate platelets in both a
heparin-dependent and -independent manner, mim-
icking an autoimmune disease (10). Theodore et al.
reported that patients with delayed-onset HIT have
high-titer platelet-activating antibodies that exhibit
increased heparin-dependent and independent plate-
let activation compared with typical-onset type (9).
It has been established that heparin-dependent an-
tibodies recognize one or more sites on platelet fac-
tor 4 (11, 12) that are conformationally modified by
pharmacologic heparin or endogenous glycosamino-
glycans, such as endothelial-bound heparin sulfate
(13, 14). Therefore, delayed-onset HIT could be
caused by high titers of heparin-dependent antibod-
ies that recognize platelet factor 4 bound to the
platelet surface in the absence of residual pharma-
cologic heparin, platelet factor 4 bound to endothe-
lial glycosaminoglycans, or both. We believe it may
be relevant to delayed-onset HIT etiology.
The first-step in establishing a diagnosis of HIT
is suspecting the presence of this syndrome. How-
ever, one major difficulty in establishing the diag-
nosis of HIT was that medical and surgical patients
Table 1. (the upper row) Results of serologic tests confirming antibodies against heparin-platelet factor 4 complexes, the IgG
antibodies detected by peculiar enzyme immunoassay on postoperative day (POD) 0, 32, 33, and 34. OD=optical density (the lower
row) The hemostatic data in POD 32.
sampling day The level of HIT antibody (%) OD value IgG of HIT antibody (OD value) Plt count(103 /μl)
Cut off 26.5 0.5 0.4
POD #0 5.2 0.112 0.083 152
POD #32 127.0 2.485 1.586 3.0
POD #33 118.3 2.314 1.640 4.0
POD #34 108.2 2.116 1.479 3.5
POD #32 value of this case normal value
D-daimer 22.5 μg/dl 0.9 μg/dl
fibrinogen degradation products(FDP) 24 μg/dl 10 μg/dl
thrombin-antithrombin complex (TAT) 10.4 ng/dl 1.8 ng/dl
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might have multiple causes for thrombocytopenia
other than the use of heparin, therefore, a pretest
clinical score (called “the 4 T’s”) have been devel-
oped and prospectively validated to be useful (15).
The “4 T’s” score of this patient was 2 points be-
cause of platelet nadir10x103 /μL and no throm-
bosis, and was interpreted as low probability for
HIT. Generally, patients with a low pretest prob-
ability of HIT do not have clinically significant HIT
antibodies. Although it was difficult to determine
whether or not HIT was present in this particular
case, the presence of a secondary fall in the platelet
count below 50 percent following arch replacement
under CPB and absence of possible drug-induced
thrombocytopenia appeared to be highly predictive
of HIT. Moreover, severe thrombocytopenia unusual
in HIT was associated with spontaneous bleeding,
reported in past literature (16). He showed a very
strongly positive HIT antibody immunoassay result,
which provided a definitive diagnosis of HIT.
Treatment of HIT consists of immediate cessation
of all exposure to heparin and alternative anticoagu-
lants that inhibit directly either coagulation factor
Xa (fondaparinux) or thrombin (argatroban) in spite
of different onset of HIT (9). He underwent an alter-
native anticoagulant therapy with argatroban during
the time remaining risk of thrombosis of other se-
quela. Argatroban was administrated from low dose
because of his hepatic impairment, and was contin-
ued until the thrombocytopenia has resolved (17).
CONCLUSION
In conclusion, if a patient manifests unexplained
severe thrombocytopenia with spontaneous bleed-
ing symptoms and heparin exposure within past 40
days, delayed-onset HIT should be kept in mind.
Heparin should be discontinued immediately and
alternative anticoagulant agents to heparin be started
for preventing thrombosis of other sequalae, and
the value of antibodies against the heparin-platelet
factor 4 complex and the specific IgG antibody be
measured simultaneously.
DECLARATION OF INTERESTS
The authors report no conflicts of interest. The
authors alone are responsible for the content and
writing of the paper.
REFERENCES
1. Murphy GS, Marymont JH : Alternative Antico-
agulation Management Strategies for the Pa-
tient With Heparin-Induced Thrombocytopenia
Undergoing Cardiac Surgery. J Cardiothorac
Vasc Anesth 21(1) : 113-126, 2007
2. Menajovsky BL : Heparin-induced thrombocy-
topenia : clinical manifestations and manage-
ment strategies. Am J Med 118 : 21-30, 2005
3. Greinacher A : Heparin-induced thrombocy-
topenia. J Thromb Haemost 7(1) : 9-12, 2009
4. Arepally GM, Ortel TL : Clinical practice : hepa-
rin-induced thrombocytopenia. N Engl J Med
355 : 809-817, 2006
5. Wan C, Warner M, DeVarennes B, Ergina P,
Cecere R, Lachapelle K : Clinical presentation,
temporal relationship, and outcome in thirty-
three patients with type 2 heparin-induced
thrombocytopenia after cardiotomy. Ann Thorc
Surg 82 : 21-27, 2006
6. Follis F, Schmidt CA : Cardiopulmonary bypass
in patients with heparin-induced thrombocy-
topenia and thrombosis. Ann Thorac Surg 70 :
2173-2181, 2000
7. Warkentin TE, Kelton JG : A 14-year study of
heparin-induced thrombocytopenia. Am J Med
101 : 502-507, 1996
8. Warkentin TE : Clinical picture of heparin-in-
duced thrombocytopenia. In : Warkentin TE,
Greinacher A, eds. Heparin-Induced Thrombo-
cytopenia. 2nd ed. Marcel Dekker Inc, New
York, 2001, pp.43-81
9. Warkentin TE, Kelton JG : Delayed-Onset Hepa-
rin-Induced Thrombocytopenia and Thrombo-
sis Ann Intern Med. 135 : 502-506, 2001
10. Warkentin TE, Makris M, Jay RM, Kelton JG :
A spontaneous prothrombotic disorder resem-
bling heparin-induced thrombocytopenia. Am
J Med 121 : 632-636, 2008
11. Horsewood P, Warkentin TE, Hayward CP,
Kelton JG : The epitope specificity of heparin-
induced thrombocytopenia. Br J Haematol 95 :
161-167, 1996
12. Ziporen L, Li ZQ, Park KS, Sabnekar P, Liu
WY, Arepally G, Shoenfeld Y, Kieber-Emmons
T, Cines DB, Poncz M : Defining an antigenic
epitope on platelet factor 4 associated with
heparininduced thrombocytopenia. Blood 92 :
3250-3259, 1998
13. Visentin GP, Ford SE, Scott JP, Aster RH : An-
tibodies from patients with heparin-induced
The Journal of Medical Investigation Vol. 60 February 2013 157
thrombocytopenia/thrombosis are specific for
platelet factor 4 complexed with heparin or
bound to endothelial cells. J Clin Invest 93 :
81-88, 1994
14. Greinacher A, Pötzsch B, Amiral J, Dummel
V, Eichner A, Mueller-Eckhardt C : Heparin-
associated thrombocytopenia : isolation of the
antibody and characterization of a multimolecu-
lar PF4-heparin complex as the major antigen.
Thromb Haemost 71 : 247-251, 1994
15. Lo GK, Juhl D, Warkentin TE, Sigouin CS,
Eichler P, Greinacher A : Evaluation of pretest
clinical score (4 T’s) for the diagnosis of
heparininduced thrombocytopenia in two clini-
cal settings. J Thromb Haemost 4 : 759-765,
2006
16. Theodore EW, Andreas G : Heparin-Induced
Thrombocytopenia and Cardiac Surgery. Ann
Thorac Surg 76 : 2121-2131, 2003
17. Lewis BE, Wallis DE, Leya F, Hursting MJ,
Kelton JG : Argatroban anticoagulation in pa-
tients with heparininduced thrombocytopenia.
Arch Intern Med 163 : 1849-1856, 2003
T. Nakayama, et al. Delayed-onset HIT158
